In another retrospective study including 282 patients treated with immunotherapy, PD‐L1 expression seemed to be more relevant for predicting the efficacy of ICIs in KRAS‐mutant NSCLC than in wild‐type NSCLC. This evidence concerns the gene KRAS and non-small cell lung carcinoma.